Inventor · disambiguated record
Brian Mingtung Chan
Also filed as: CHAN BRIAN · CHAN BRIAN M · CHAN BRIAN MINGTUNG
7 granted patents·7 pending applications·12 citations·filing 2014–2024
77Inventor score
Top patents by PatentIndex Score
14 records- 0187US10059766B2Antibody constructs for CDH19 and CD3AMGEN RES MUNICH GMBH·Filed 2014·Granted Aug 28, 2018·9 cites·17 claims
- 0281US11053311B2Antibodies targeting CDH19 for melanomaAMGEN INC·Filed 2018·Granted Jul 6, 2021·1 cites·25 claims
- 0381US2025084160A1Antibodies targeting cdh19 for melanomaAMGEN INC·Filed 2024·Application pending·0 cites
- 0481US2025051457A1Asgr inhibitorsAMGEN INC·Filed 2024·Application pending·0 cites
- 0579US11498964B2Antibody constructs for CDH19 and CD3AMGEN RES MUNICH GMBH·Filed 2018·Granted Nov 15, 2022·1 cites·17 claims
- 0678US12441796B2Antibody constructs for CDH19 and CD3AMGEN INC·Filed 2022·Granted Oct 14, 2025·0 cites·17 claims
- 0770US9920121B2Antibodies targeting CDH19 for melanomaAMGEN INC·Filed 2014·Granted Mar 20, 2018·1 cites·25 claims
- 0870US2022127354A1Antibodies targeting cdh19 for melanomaAMGEN INC·Filed 2021·Application pending·0 cites
- 0965US12331122B2Anti-ASGR-1 monoclonal inhibitory antibodiesAMGEN INC·Filed 2020·Granted Jun 17, 2025·0 cites·17 claims
- 1062US2024103009A1Non-terminal antibody discovery methods and single cell assaysAMGEN INC·Filed 2022·Application pending·0 cites
- 1162US2020071405A1Antibody constructs for cdh19 and cd3AMGEN RES MUNICH GMBH·Filed 2019·Application pending·0 cites
- 1252US11505614B2Antibodies binding to soluble BCMAAMGEN INC·Filed 2019·Granted Nov 22, 2022·0 cites·28 claims
- 1352US2024117069A1Materials and Methods for Monitoring Cancer by Administering an Anti-MCL1 AntibodyAMGEN INC·Filed 2022·Application pending·0 cites
- 1447US2023314417A1Monoclonal antibodies to chemically-modified nucleic acids and uses thereofAMGEN INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Brian Mingtung Chan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →